Collaborations Between Public and Private Sector Are Critical to Advance Alzheimer's Research

 

 

WASHINGTON, Feb. 7, 2012 /PRNewswire-USNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani responded to new efforts unveiled today by the Administration to combat Alzheimer's Disease: 

(Logo: http://photos.prnewswire.com/prnh/20091027/PHRMALOGO)

"Alzheimer's disease is one of America's top health challenges. It ravages the minds of patients, seriously impacts entire families and currently costs the U.S. health care system $172 billion a year. According to the Alzheimer's Association, an American will develop the disease every 33 seconds in 2050, costing the U.S. health care system $1.1 trillion. These costs are simply unsustainable. 

"The outlook could change course, however, if a treatment were discovered that helps delay the onset of Alzheimer's. Biopharmaceutical research companies, recognizing the great health and economic need to help delay or prevent the onset of Alzheimer's, have invested heavily in this area and are currently researching and developing nearly 100 medicines to help address this public health priority.

"Discovering an Alzheimer's treatment is by no means an easy task; and it can certainly benefit from collaborations between industry, academia and federal research institutions. In addition to their individual efforts to discover and develop novel treatments for Alzheimer's, biopharmaceutical companies have partnered with each other and with academic and federal research institutions to help move forward the scientific understanding of this complex disease. One remarkable example is provided by the Alzheimer's Disease Neuroimaging Initiative (ADNI), a large five year research project to define the rate of progress of Alzheimer's disease, develop improved methods for clinical trials in this area, and to provide a large database which may improve development of innovative treatments.

"We look forward to continuing our engagement with the different stakeholders and constituents involved in this national charge to combat Alzheimer's."

Click here for more information about all of the incredible work that biopharmaceutical research companies are doing to help find a treatment for Alzheimer's. 

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.4 billion in 2010 in discovering and developing new medicines. Industry-wide research and investment reached a record $67.4 billion in 2010. 

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org

SOURCE Pharmaceutical Research and Manufacturers of America



RELATED LINKS
http://www.phrma.org

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.